An interventional study of Higher protein dietary pattern and Calorie restriction in Polycystic Ovary Syndrome (PCOS), sponsored by University of Arkansas, Fayetteville. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by University of Arkansas, Fayetteville · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 183 studies in Polycystic Ovary Syndrome with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Polycystic Ovary Syndrome · United States.
Among the 183 studies in Polycystic Ovary Syndrome with a site in United States, this one is the 47th largest by planned enrollment of the 146 interventional ones that give a count, is one of 6 that started in 2025, is one of 74 with no phase, reaches primary completion later than 29 of the 41 other live ones, and was the 175th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →32 of the 183 studies in Polycystic Ovary Syndrome with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18–40 · Women only
University of Chicago · Sites in United States
Ages 18–40 · Women only
Texas A&M University · Sites in United States
Ages 11–17 · Women only
University of Wisconsin, Madison · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 8+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
183 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 20 · Phase 3 16 · Phase 4 14
First in 1997; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 39 across the 146 interventional studies, 65 across the 35 observational. Of the 122 that completed or were terminated, 57 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 183 have an industry lead sponsor. The 10 most frequent:
University of Arkansas, Fayetteville is the lead sponsor of 29 studies on the registry; 7 are open to participants now.
University of Arkansas, Fayetteville has 2 studies filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
10 of the studies in Polycystic Ovary Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04407754University of OklahomaMyo-Inositol for Infertility in PCOS | 2026-12 |
| NCT07227363Ohio State UniversitySymptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation Pilot | 2026-12 |
| NCT07392476The Cleveland ClinicContinuous Glucose Monitoring in Polycystic Ovarian Syndrome | 2026-12-31 |
| NCT07142603University of Arkansas, FayettevilleAppetite Response to Meals With Different Protein Sources in Women With PCOS | 2026-12-31 |
| NCT07571915The Cleveland ClinicHealth-Related Quality of Life and Metabolic Outcomes in PCOS | 2027-05-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 183 studies in Polycystic Ovary Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Polycystic ovary syndrome (PCOS) is a significant public health problem and is one of the most common hormonal disturbances affecting women of reproductive age. Women with PCOS are often insulin resistant, increasing their risk for cardiometabolic health problems (e.g., type 2 diabetes, heart disease, high blood pressure, sleep apnea, anxiety, depression, and stroke) especially if they are overweight. Lifestyle modifications, including dietary changes and regular physical activity, may alleviate metabolic dysfunction in women with PCOS and are often the first line of management for patients with PCOS. Several studies have identified protein as a key nutrient for regulation of energy balance, maintenance of skeletal muscle mass, and improving cardiometabolic health across the lifespan. However, the effect of increased protein intake (30% of total energy intake) on cardiometabolic health in women with PCOS has not been well-defined and mechanisms for these effects have not been identified.
There is an evident need for well-designed, randomized controlled trials evaluating the efficacy of increased protein intake in women with PCOS on markers of cardiometabolic health. Preliminary data from collaborative projects with the investigators on this proposal suggest that increasing protein in the diet has the potential to improve markers of cardiometabolic health, potentially through improvements in body composition and/or changes in cortisol, energy metabolism, inflammation, and neurological regulators
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Calorie restriction
Other: Higher protein dietary pattern
Other: Calorie restriction
Other: Higher protein dietary pattern
Follow energy-restricted (10% calorie reduction), higher protein dietary pattern (1.6 g protein/kg body weight)
Follow energy-restricted (10% calorie reduction) dietary pattern for 16 weeks. No restrictions on macronutrient content.
Lean body mass
Lean body mass will be measured using dual x-ray absorptiometry.
Time frame: 0 and 16 weeks.
Body fat mass
Total body fat and body fat distribution will measured using dual x-ray absorptiometry.
Time frame: 0 and 16 weeks
Sleep Duration
Sleep quality and duration will be assessed objectively via an ActiGraph triaxial wrist accelerometer GT3X+, ActiGraph, LLC, Pensacola, FL, USA), a validated method of sleep assessment. Each participant will wear an ActiGraph monitor on the non-dominant wrist for 24-hour per day for seven days (except when bathing or involved in water activities) prior to the start of the intervention, 8-, and 16-weeks. Actigraphs will be fitted securely on each participants wrist. Participants will receive sleep diaries to define "time in bed" and "time out of bed". Researchers will use the indicated "start" and "end" points to define a sleep region to be analyzed within the ActiGraph software. Sleep outcomes will be calculated based on epoch-to-epoch sleep/wake algorithms within the defined sleep period. Data were processed by using the ActiLife Version 6.9.2 software (Pensacola, FL, USA) and sleep will be scored via the Cole-Kripke algorithm.
Time frame: Sleep will be measured every 8 weeks (0, 8, and 16 weeks)
Mood
The Profile of Mood States (POMS) questionnaire consists of 65 questions containing a one-word adjective of mood to measure and identify six affective states. The six identifiable mood/affective states are tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue/-inertia, and confusion-bewilderment. Participants will be instructed to define their mood on a 5-point Likert scale ranging from 0 to 4. The numbers refer to the following descriptive phrases: 0 = Not at all, 1 = A little, 2 = Moderately, 3 = Quite a bit, 4 = Extremely. To obtain the score for reach identifiable mood/affective state subscale, the sum of the responses for each adjective is calculated. The subscale scores range from 0 up to 36, 60, 48, 32, 28, and 28 for tension-anxiety depression-dejection, anger-hostility, vigor-activity, fatigue/-inertia, and confusion-bewilderment respectively. Higher subscale scores for all affect states, but the vigor domain represent poorer mood.
Time frame: Every 4 weeks (0, 4, 8, 12, 16 weeks)
Quality of Life perception
Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). The instrument consists of 36 items grouped into eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Items will be scored using standard Likert-type response scales and coded according to established procedures. Raw scores for each domain were summed and linearly transformed to a 0-100 scale, with higher scores indicating better health status.
Time frame: Every 4 weeks (0, 4, 8, 12, and 16 weeks)
Energy expenditure
Indirect calorimetry will be used to measure energy expenditure
Time frame: Every 4 weeks (0, 4, 8, 12 and 16 weeks)
Plasma amino acid concentrations
Plasma amino acids will be measured using UPL.
Time frame: Every 4 weeks (0, 4, 8, 12 and 16 weeks).
Inflammatory biomarkers
Inflammatory status will be evaluated using established circulating biomarkers that reflect systemic, low-grade inflammation. The primary analytes include high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). hs-CRP is an acute-phase reactant produced by the liver and is widely used as a sensitive indicator of chronic inflammation and cardiovascular risk. IL-6 is a pro-inflammatory cytokine that plays a central role in immune regulation and metabolic function, while TNF-α is a key mediator of systemic inflammation and tissue catabolism. Together, these biomarkers provide complementary information on both acute-phase and cytokine-mediated pathways of inflammation and are commonly used in clinical and epidemiological studies to quantify inflammatory burden.
Time frame: Every 4 weeks (0, 4, 8, 12, and 16 weeks).
Subjective Sleep Measurements
Subjective measure of sleep quality will be assessed via the Pittsburgh Sleep Quality Index (PSQI) . The 19-item PSQI questionnaire addresses seven components of subjective sleep quality: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global sleeping score (GSS) with a range of 0 to 21. Higher scores indicate worse sleep quality. A compiled global score of the seven scored components distinguishes good sleepers (≤ 5) from poor sleepers (\>5). According to a test-retest reliability and validity experiment, as a marker for sleep disturbances, a PSQI GSS \> 5 has a sensitivity of 98.7 and specificity of 84.4.
Time frame: Subjective sleep will be measured at 0, 4, 8, 12, and 16 weeks.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.
Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 22 months is above that.
Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Arkansas, Fayetteville